clinical trial · NCT00154323
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.
Novartis·phase4·completed·n = 55
Bipolar DisorderOxcarbazepine
brief summary
Bipolar disorder is a psychiatric illness with clinical characteristics of mixed mania, grandiose delusions, and suicidality. This study will investigate the efficacy a safety of oxcarbazepine in the treatment of patients with bipolar disorder type I or II.
started
Jan 1, 2003
primary completion
Jan 1, 2006
completion
Jan 1, 2006
last updated
Dec 14, 2023
official title
A Multi-center, Randomized, Double-blind, Parallel Group, Placebo-controlled 52 Weeks Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o.(300-1200 mg/Day) as Adjuvant Therapy in the Bipolar Disorder I or II Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol